Law Offices of Howard G. Smith Reminds Investors Of The Lead Plaintiff Deadline In The Class Action Lawsuit Against Aegerion Pharmaceuticals, Inc.
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors that all purchasers of the securities of Aegerion Pharmaceuticals, Inc. (“Aegerion” or the “Company”) (NASDAQ:AEGR) between March 15, 2012 and January 9, 2014, inclusive (the “Class Period”), have until March 17, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
The Complaint filed in the United States District Court for the District of Massachusetts alleges that Aegerion’s marketing practices during the Class Period were in violation of the Food, Drug, and Cosmetic Act (FDCA), and that defendants made false and misleading statements or failed to disclose to Aegerion investors that the Company marketed its drugs in violation of the FDCA. On January 10, 2014, Aegerion received a subpoena from the U.S. Department of Justice requesting documents regarding its marketing and sale of Juxtapid -- a treatment for patients with homozygous familial hypercholesterolemia. As a result of this news, Aegerion shares declined $ 7.98 per share, or nearly 11%, to close at $65.77 per share on January 10, 2013.
If you purchased Aegerion securities during the Class Period, you may move the Court no later than March 17, 2014, to serve as lead plaintiff, if you meet certain legal requirements. To be a member of the Class, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you purchased Aegerion stock prior to March 15, 2012, and still hold those shares, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to firstname.lastname@example.org, or visit our website at http://www.howardsmithlaw.com.